Literature DB >> 16224548

Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonists in experiments on isolated perfused rat heart.

A V Krylatov1, L N Maslov, O V Lasukova, R G Pertwee.   

Abstract

We studied the effect of selective cannabinoid receptor ligands on contractility of isolated Langendorff-perfused rat heart. It was found that 10-min perfusion of rat heart with a solution containing selective agonist of CB1 and CB2 receptors HU-210 (10 nM) decreased left ventricular developed pressure and maximum rates of contraction and relaxation. However, HU-210 had no effect on heart rate and end-diastolic pressure. Treatment with selective CB1 receptor antagonist SR141716 (1 microM) and selective CB2 receptor antagonist SR144528 (1 microM) decreased left ventricular developed pressure and maximum rates of contraction and relaxation, but had no effect on heart rate and end-diastolic pressure. Ten-minute perfusion of rat heart with a solution containing selective agonist of CB1 and CB2 receptors HU-210 (10 nM) decreased cAMP concentration in the heart. CB receptor antagonists had little effect on cAMP concentration in the heart. The negative inotropic effect of HU-210 and CB receptor antagonists is probably mediated by activation of CB1 receptors. It can be hypothesized that the decrease in heart cAMP concentration is related to stimulation of CB2 receptors. Our results suggest that selective CB receptor antagonists SR141716 and SR144528 in a final concentration of 1 microM exhibit properties of partial CB receptor agonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16224548     DOI: 10.1007/s10517-005-0344-9

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  12 in total

Review 1.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  The effects of targeted deletion of cannabinoid receptors CB1 and CB2 on intranasal sensitization and challenge with adjuvant-free ovalbumin.

Authors:  Barbara L F Kaplan; Jody E Lawver; Peer W F Karmaus; Thitirat Ngaotepprutaram; Neil P Birmingham; Jack R Harkema; Norbert E Kaminski
Journal:  Toxicol Pathol       Date:  2010-02-26       Impact factor: 1.902

Review 3.  Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?

Authors:  Nikolaos Garmpis; Christos Damaskos; Dimitrios Dimitroulis; Anna Garmpi; Evangelos Diamantis; Panagiotis Sarantis; Vasiliki E Georgakopoulou; Alexandros Patsouras; Dionysios Prevezanos; Athanasios Syllaios; Georgios Kyriakos; Evangelos Koustas; Markos Despotidis; Christos Vallilas; Petros Papalexis; Efstathios A Antoniou; Konstantinos Kontzoglou; Gregory Kouraklis
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

Review 4.  Endocannabinoids and the gastrointestinal tract: what are the key questions?

Authors:  G J Sanger
Journal:  Br J Pharmacol       Date:  2007-09-03       Impact factor: 8.739

Review 5.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

6.  Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.

Authors:  Alison E B Springs; Peer W F Karmaus; Robert B Crawford; Barbara L F Kaplan; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2008-09-12       Impact factor: 4.962

Review 7.  Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

Authors:  Hester van Diepen; Eberhard Schlicker; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-25       Impact factor: 3.000

8.  Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats.

Authors:  Michelle Roche; John P Kelly; Maeve O'Driscoll; David P Finn
Journal:  Immunology       Date:  2008-04-03       Impact factor: 7.397

9.  Cannabinoid Receptor Agonist Inhibits Atrial Electrical Remodeling in a Tachypaced Ex Vivo Rat Model.

Authors:  Danielle I Lee; Michael Murninkas; Sigal Elyagon; Yoram Etzion; Hope D Anderson
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

10.  Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.

Authors:  M Donadelli; I Dando; T Zaniboni; C Costanzo; E Dalla Pozza; M T Scupoli; A Scarpa; S Zappavigna; M Marra; A Abbruzzese; M Bifulco; M Caraglia; M Palmieri
Journal:  Cell Death Dis       Date:  2011-04-28       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.